Mélanie Thill-Tayara

NORTON ROSE - 25 & 26/05/2010 - PARIS

Mélanie Thill-Tayara

Mélanie Thill-Tayara is a partner in Dechert’s Paris office. She focuses her practice on antitrust and competition law, and she regularly represents leading companies in merger notifications before the French and European regulators and coordinates multi-jurisdictional filings. She has handled a significant number of cartel and abuse of dominant position cases before EU and French authorities and courts.

Noted as a strong litigator whose “advice is invaluable [and] always technically accurate,” she has been involved in landmark cases involving essential facilities, information exchange systems and dominance abuses in various sectors. “She is held in high esteem by clients, one of whom reports with her experience she is probably someone who really makes an impact and a difference” (Chambers). Noted as “a must” with respect to life sciences, pharmaceuticals and biotechs, she also counsels clients on issues pertaining to sectors such as financial services, consumer goods, luxury goods and leisure, transport, technology goods, chemicals and press distribution (Leaders League). Named Top Woman in Antitrust and listed as a leading competition lawyer in France in GCR 100, 2016, Mélanie Thill-Tayara is recognized as a leading lawyer by Who’s Who Legal: France 2017 – Competition and Life Sciences and by Best Lawyers France 2018 in Biotechnology and Life Sciences as well as in Competition / Antitrust Law.

Ms. Thill-Tayara has substantial experience in the areas of internal audits, compliance programs, mock dawn raid operations and competition law employee trainings, and regularly advises clients involved in inspections conducted by the authorities and the subsequent challenges.

She is a frequent author and speaker on various issues pertaining to antitrust and competition laws.

Prior to joining Dechert in February 2016, she served as a partner for more than 20 years with two other international law firms. Before that she was an officer at the European Commission, Directorate General for Competition, where she participated in numerous dawn raid operations and contributed to several decisions.

Significant Representations

  • A German operator in the context of a cartel procedure before the French Competition Authority and the Paris Court of Appeals for the practices carried out by a former subsidiary.
  • A global healthcare leader in first instance and appeal, in a dispute against a biotech startup, relating to the termination of negotiations to invest in the development of new cancer-fighting molecules.
  • A leading actor in the field of retirement houses and other specialized care centers, on merger control issues related to the projected acquisition of a controlling stake in Belgium groups.
  • A financial services operator in the European Commission's investigation on alleged conducts by seven European banks involving the manipulation of Euribor, the benchmark used, among other things, when pricing bank lending in euros and euro interest rate derivatives.
  • FMCG companies in various matters such as: the launching of a new product subject to strict regulations, the analysis of the risk of dominant position on primary and secondary markets related to an innovative range of products; the organization of internal training programs relating to competition, distribution and regulatory rules; the implementation of a joint venture with a competitor; the subscription to a European buying group.
  • A major international medical devices company during a dawn-raid conducted by the French Competition Authority relating to an alleged anticompetitive agreement and the subsequent procedural challenges; she succeeded in having the case dismissed by the French competition authority.
  • A major international medical devices company on the antitrust and public procurement aspects of a “dual branch” business model implemented across Europe for the supply of medical devices to public hospitals.
  • A French supplier of luxury products in the design and implementation of its national and international selective distribution networks, as well as other diverse matters: management of parallel imports matters, negotiation and drafting of licensing agreements for the manufacturing of eyewear, and the negotiation of leases for high-end location boutiques.
  • A US-based biopharmaceutical company in an ongoing investigation led by the European Commission with respect to anti-generic strategies, and particularly patent settlements.
  • Leading international and national pharmaceutical companies in designing the re-organization of their European and national distribution networks in order to decrease the number of their suppliers and increase efficiencies whilst complying with sectorial regulations and obligations of public service.
  • A multinational biotechnology company both on competition and regulatory aspects of an investigation relating to alleged collective dominance and concerted practices of two pharmaceutical companies for having differentiated the therapeutic indications of their products.
  • A leading international and national pharmaceutical companies in designing the re-organization of their European and national distribution networks in order to decrease the number of their suppliers and increase efficiencies whilst complying with sectorial regulations and obligations of public service.
  • A life sciences company in the interaction with the French professional medical devices association and the French authorities in charge of pricing and reimbursement.
  • A US-based laboratory in relation to an in-depth audit of regulatory compliance (French and US) with regard to clinical trials, grants, congresses, interactions with healthcare professionals and government officers; the audit included interviews with reps and the creation of a detailed database of professional expenses with specialized forensic auditors; assisting the client in the review of internal policies in this field.
  • An international information technology company providing hardware and software services to consumers, businesses and public customers in cases relating to comparative advertising and abuse of an economic dependency.
  • Major companies with respect to their merger filings before the European Commission, the French competition authority and the Moroccan competition authorities.
  • A leading research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, in an assessment of life cycle management strategies in reaction to the expected launch of bio-similar products.
  • A leading research-focused healthcare on the implementation of an internal compliance programme, including the organisation of a mock dawn-raid.
  • A Swiss based diagnostic medical device company concerning the possibility to oppose to parallel trade of one of its major products, due to safety reasons.

Includes matters handled at Dechert or prior to joining the firm.

Education
  • Université Paris 1 Panthéon-Sorbonne, DEA, -2147483648
  • Université Paris 1 Panthéon-Sorbonne, DEA, Business Law and Private International Law, -2147483648
  • Centre Universitaire d’Etudes Communautaires, Diploma, -2147483648
  • Université Paris 1 Panthéon-Sorbonne, Maîtrise, -2147483648
  • Université Paris 1 Panthéon-Sorbonne, Maîtrise, International and European Law, -2147483648
  • University of Munich, Diploma, -2147483648
  • University of Munich, Diploma, Political Sciences, -2147483648
Languages
  • French
  • English
  • German
  • Italian
Memberships
International Bar Association
Association Française de l’Etude de la Concurrence
APDC
Studienvereinigung Kartellrecht
Board and Executive Committee, Association des Avocats Pratiquant le Droit de la Concurrence